Allon Therapeutics

Alzheimer drug maker reports clinical update, $0.05 per share loss

Published in Lab Business Week, September 25th, 2005

Allon Therapeutics, Inc., (NPC) reported in its second quarter 2005 operating results that it achieved all of its performance milestones, including positive results from its phase Ia human clinical trial evaluating lead product AL-108 as a treatment for Alzheimer disease and preparations to begin a phase Ib clinical trial in Q3 2005.

The company also filed an investigational new drug application (IND) with the U.S. Food and Drug Administration for approval to begin human clinical trials to evaluate the company's second drug candidate AL-208 as a treatment for mild cognitive impairment (MCI) associated with cardiac artery bypass graft (CABG) surgery. Allon will commence...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry